Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel application of carbocisteine

A technology of cysteine ​​and carboxymethyl, which is applied in the field of new drug use of salt, can solve problems such as bronchiectasis that has not been reported in reports, and achieve the effect of improving oxidative stress

Inactive Publication Date: 2017-01-11
GUANGZHOU BAIYUNSHAN PHARMA HLDG CO LTD BAIYUNSHAN PHARMA GENERAL FACTORY +1
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Carbocisteine ​​has certain antioxidant and anti-inflammatory effects, but there is no report on bronchiectasis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel application of carbocisteine
  • Novel application of carbocisteine
  • Novel application of carbocisteine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1 The preparation of tablet of the present invention

[0045] S-(carboxymethyl)-L-cysteine ​​500 g

[0046] Pregelatinized starch 500g

[0047] Magnesium stearate 10g

[0048] Fully mix 500g of the above S-(carboxymethyl)-L-cysteine ​​and 500g of pregelatinized starch, add water to make a soft material, granulate, dry the whole material, add magnesium stearate, and press into tablets There are 1000 tablets in total, each containing 500mg of S-(carboxymethyl)-L-cysteine.

Embodiment 2

[0049] Example 2 The preparation of granules of the present invention

[0050] S-(carboxymethyl)-L-cysteine ​​500 g

[0051] Pregelatinized starch 500g

[0052] Magnesium stearate 10g

[0053] Fully mix 500g of the above-mentioned S-(carboxymethyl)-L-cysteine ​​and 500g of pregelatinized starch, make soft material, granulate, dry, and bag after granulation, a total of 1000 bags, each bag contains S-(carboxymethyl)-L-cysteine ​​500mg.

Embodiment 3

[0054] Example 3 The preparation of oral solution of the present invention

[0055] S-(carboxymethyl)-L-cysteine ​​500 g

[0056] Sucrose 500g

[0057] Flavor Appropriate amount

[0058] add water to 1000mL

[0059] Fully mix and dissolve the above S-(carboxymethyl)-L-cysteine ​​500g, sucrose 500g and appropriate amount of essence, add water to 1000mL, divide into 10mL / bottle, 1000 bottles in total, each tablet contains S-(carboxymethyl) Methyl)-L-cysteine ​​500mg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a novel application of a medicament, and specifically relates to an application of carbocisteine and pharmaceutically acceptable salts thereof to preparation of the medicament for preventing or treating bronchiectasis. Carbocisteine and pharmaceutically acceptable salts thereof are used for substantially inhibiting oxidative stress and inflammatory injury of bronchiectasis model animals, so that carbocisteine and pharmaceutically acceptable salts thereof can be applied to preparation of the medicament for preventing or treating bronchiectasis.

Description

technical field [0001] The invention relates to the field of medicine, in particular, the invention relates to a new medicine application of S-(carboxymethyl)-L-cysteine ​​and a pharmaceutically acceptable salt thereof. Background technique [0002] Bronchiectasis (bronchiectasis, referred to as "bronchiectasis") refers to the chronic inflammation and airway obstruction of the bronchi and its surrounding tissues, resulting in serious pathological damage to the structure of the bronchi, causing dilation and deformation of the lumen. Typical clinical symptoms include chronic cough, coughing up a large amount of purulent sputum, and repeated hemoptysis. The main pathogenic factors of bronchiectasis are bronchial infection, obstruction and traction, and some have congenital genetic factors. Most patients have a history of measles, whooping cough or bronchopneumonia. Infection is the most common cause of bronchiectasis (Gao Y, Guan W, Xu G, et al . The role of viral infection ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/198A61P11/08A61P11/06A61P29/00A61P11/00
Inventor 朱少璇钟南山郑劲平王玮陈荣昌关伟杰王健松陈红英郭春梅
Owner GUANGZHOU BAIYUNSHAN PHARMA HLDG CO LTD BAIYUNSHAN PHARMA GENERAL FACTORY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com